Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs FuelCell Energy Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while FuelCell Energy Inc trades at $20.29 (market cap $1.71B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.7× FuelCell Energy Inc's market cap. Which is the better fit depends on your goals.
| BIO | FCEL | |
|---|---|---|
Market Cap | $8.04B | $1.71B |
Sector | Health | Industrials |
52-Week High | $339.75 | $36.01 |
52-Week Low | $241.71 | $3.92 |
Enterprise Value | $7.85B | $1.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FuelCell Energy (FCEL) trades at $19.08, down 9.27% in the last session, as the stock consolidates following recent volatility. The company reported mixed Q1 2026 results with an earnings miss but continues to show revenue growth, with 2025 revenue reaching $158.16M. Technical indicators show a bearish trend with key support at $17-18 levels. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225 million stock offering that caused temporary dilution concerns.
FCEL presents a high-risk opportunity with strong growth potential in the fuel cell sector but faces significant fundamental challenges. The company maintains negative profitability metrics and cash burn, though recent partnerships and data center demand provide catalysts. Analyst consensus is mixed with a $20.75 price target representing 8.8% upside, but investors should weigh the growth narrative against persistent losses and dilution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
